NRC vs DBVT vs SATS vs ALKS

For growth investors, National Research Corporation (NRC) is the stronger pick with -4.

0% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 29. 5x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 29.

5x versus National Research Corporation at 37. 6x.

Over the past 5 years, EchoStar Corporation (SATS) delivered a total return of +374.

8%, compared to -66. 9% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: SATS returned +222. 7% versus DBVT's -88. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), National Research Corporation (NRC) is the lower-risk stock at 0.

80β versus EchoStar Corporation's 1. 72β — meaning SATS is approximately 114% more volatile than NRC relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 6% for National Research Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), National Research Corporation (NRC) is pulling ahead at -4.

0% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Alkermes plc grew EPS -34. 1% year-over-year, compared to -113. 6% for EchoStar Corporation. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -155. 1% for EchoStar Corporation — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -118. 1% for SATS. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 142.

6% to $46. 33.

In this comparison, NRC (2.

5% yield) pays a dividend. DBVT, SATS, ALKS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, National Research Corporation (NRC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

80), 2. 5% yield). EchoStar Corporation (SATS) carries a higher beta of 1. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NRC: +91. 8%, SATS: +222. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NRC (Healthcare) and DBVT (Healthcare) and SATS (Technology) and ALKS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

NRC pays a dividend while DBVT, SATS, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.